OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma

Overview

Journal Front Genet

Date 2020 Mar 11

PMID 32153627

Citations 15

Authors

Huan Dong

Qiang Wang

Ning Li

Jiajia Lv

Linna Ge

Mengsi Yang

Guosen Zhang

Yang An

Fengling Wang

Longxiang Xie

Yongqiang Li

Wan Zhu

Haiyu Zhang

Minghang Zhang

Xiangqian Guo

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is the most common malignant tumor of the central nervous system. GBM causes poor clinical outcome and high mortality rate, mainly due to the lack of effective targeted therapy and prognostic biomarkers. Here, we developed a user-friendly Online Survival analysis web server for GlioBlastoMa, abbreviated OSgbm, to assess the prognostic value of candidate genes. Currently, OSgbm contains 684 samples with transcriptome profiles and clinical information from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Chinese Glioma Genome Atlas (CGGA). The survival analysis results can be graphically presented by Kaplan-Meier (KM) plot with Hazard ratio (HR) and log-rank value. As demonstration, the prognostic value of 51 previously reported survival associated biomarkers, such as (HR = 2.4120, = 0.0071) and (HR = 1.5578, 0.001), were confirmed in OSgbm. In summary, OSgbm allows users to evaluate and develop prognostic biomarkers of GBM. The web server of OSgbm is available at http://bioinfo.henu.edu.cn/GBM/GBMList.jsp.

Citing Articles

Genealogical tracing of Olea europaea species and pedigree relationships of var. europaea using chloroplast and nuclear markers.

Mariotti R, Belaj A, de la Rosa R, Muleo R, Cirilli M, Forgione I BMC Plant Biol. 2023; 23(1):452.

PMID: 37749509 PMC: 10521521. DOI: 10.1186/s12870-023-04440-3.

Identification and characterization of putative biomarkers and therapeutic axis in Glioblastoma multiforme microenvironment.

Kumari S, Kumar P Front Cell Dev Biol. 2023; 11:1236271.

PMID: 37538397 PMC: 10395518. DOI: 10.3389/fcell.2023.1236271.

Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven Approach.

Behrooz A, Latifi-Navid H, da Silva Rosa S, Swiat M, Wiechec E, Vitorino C Cancers (Basel). 2023; 15(12).

PMID: 37370767 PMC: 10296097. DOI: 10.3390/cancers15123158.

Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.

Rosli A, Azlan A, Rajasegaran Y, Mot Y, Heidenreich O, Mohd Yusoff N Clin Exp Med. 2022; 23(4):1137-1159.

PMID: 36229751 DOI: 10.1007/s10238-022-00913-1.

High APLN Expression Predicts Poor Prognosis for Glioma Patients.

Lv S, An Y, Dong H, Xie L, Zheng H, Cheng X Oxid Med Cell Longev. 2022; 2022:8393336.

PMID: 36193059 PMC: 9526648. DOI: 10.1155/2022/8393336.

References

Meng D, Chen Y, Zhao Y, Wang J, Yun D, Yang S . Expression and prognostic significance of TCTN1 in human glioblastoma. J Transl Med. 2014; 12:288. PMC: 4198629. DOI: 10.1186/s12967-014-0288-9. View

Sano T, Lin H, Chen X, Langford L, Koul D, Bondy M . Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999; 59(8):1820-4. View

Cheng Y, Tsai W, Sung Y, Chang H, Chen Y . Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells. Cell Physiol Biochem. 2018; 45(2):819-831. DOI: 10.1159/000487174. View

Rosati A, Poliani P, Todeschini A, Cominelli M, Medicina D, Cenzato M . Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol. 2013; 15(5):618-25. PMC: 3635515. DOI: 10.1093/neuonc/nos338. View

Zupancic K, Blejec A, Herman A, Veber M, Verbovsek U, Korsic M . Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach. Radiol Oncol. 2014; 48(3):257-66. PMC: 4110082. DOI: 10.2478/raon-2014-0014. View

Lee D, Suh Y, Park T, Do I, Seol H, Nam D . Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas. J Surg Oncol. 2012; 107(6):646-52. DOI: 10.1002/jso.23249. View

Xie L, Dang Y, Guo J, Sun X, Xie T, Zhang L . High Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients. Genes (Basel). 2019; 10(1). PMC: 6360019. DOI: 10.3390/genes10010036. View

Cui X, Xu Z, Zhao Z, Sui D, Ren X, Huang Q . Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma. Int J Biol Sci. 2013; 9(2):134-41. PMC: 3572395. DOI: 10.7150/ijbs.4891. View

Dahlrot R, Dowsett J, Fosmark S, Malmstrom A, Henriksson R, Boldt H . Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. Neuropathol Appl Neurobiol. 2017; 44(2):172-184. DOI: 10.1111/nan.12415. View

10.

Li F, Li Y, Zhang K, Li Y, He P, Liu Y . as candidate gene associated with long-term and short-term survival with primary glioblastoma. Onco Targets Ther. 2017; 10:387-395. PMC: 5248947. DOI: 10.2147/OTT.S117165. View

11.

Lv J, Yang H, Wang X, He R, Ding L, Sun X . Decreased BRMS1L expression is correlated with glioma grade and predicts poor survival in glioblastoma via an invasive phenotype. Cancer Biomark. 2018; 22(2):311-316. DOI: 10.3233/CBM-171019. View

12.

Shirai K, Suzuki Y, Oka K, Noda S, Katoh H, Suzuki Y . Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol. 2008; 91(3):353-8. DOI: 10.1007/s11060-008-9720-4. View

13.

Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B . Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016; 18(8):1099-108. PMC: 4933482. DOI: 10.1093/neuonc/now021. View

14.

Cai H, Cheng Z, Zhang H, Wang P, Zhang Y, Hao J . Overexpression of MCM6 predicts poor survival in patients with glioma. Hum Pathol. 2018; 78:182-187. DOI: 10.1016/j.humpath.2018.04.024. View

15.

Zhang G, Wang Q, Yang M, Yuan Q, Dang Y, Sun X . OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients. Front Oncol. 2019; 9:466. PMC: 6593271. DOI: 10.3389/fonc.2019.00466. View

16.

Wang Q, Wang F, Lv J, Xin J, Xie L, Zhu W . Interactive online consensus survival tool for esophageal squamous cell carcinoma prognosis analysis. Oncol Lett. 2019; 18(2):1199-1206. PMC: 6607102. DOI: 10.3892/ol.2019.10440. View

17.

Bai Y, Zhang Q, Wang X . Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome. Eur J Med Res. 2014; 19:66. PMC: 4279594. DOI: 10.1186/s40001-014-0066-4. View

18.

Zhao J, Tang H, Zhao H, Che W, Zhang L, Liang P . SEMA6A is a prognostic biomarker in glioblastoma. Tumour Biol. 2015; 36(11):8333-40. DOI: 10.1007/s13277-015-3584-y. View

19.

Han M, Xu R, Xu Y, Zhang X, Ni S, Huang B . TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas. J Exp Clin Cancer Res. 2017; 36(1):155. PMC: 5674233. DOI: 10.1186/s13046-017-0619-9. View

20.

Hayashi T, Hayakawa Y, Koh M, Tomita T, Nagai S, Kashiwazaki D . Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma. Neuropathology. 2017; 38(2):144-153. DOI: 10.1111/neup.12446. View